Drug Profile
Research programme: inflammatory disease therapeutics - Galapagos NV
Latest Information Update: 28 Aug 2020
Price :
$50
*
At a glance
- Originator Galapagos NV
- Class Small molecules
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Inflammation
Most Recent Events
- 28 Aug 2020 No recent reports of development identified for research development in Inflammation in Belgium
- 16 Jul 2016 No recent reports of development identified for research development in Inflammation in Belgium
- 04 Feb 2011 Galapagos NV and Merck & Co. end their strategic alliance